RECORDATI: PUBLIC DISCLOSURE

Milan, 16 March 2018 – Please be informed that the **Directors' Reports** relating to the item 1 (Financial statement's approval and allocation of profit); item 2 (Remuneration policies); item 3 (Approval of the stock Options plan 2018-2022) and item 4 (Purchase and utilization of treasury stock) of the agenda of the Ordinary Shareholders' Meeting called for April 18th 2018, single call, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "1info" storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations
Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com